Abdul Kadir, MD
Neurology · Odessa, TXNPI 1548312390
Payments from drug & device makers
Across 400 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$907
- UCB, Inc.$826
- Teva Pharmaceuticals USA, Inc.$572
- Biogen$570
- Supernus Pharmaceuticals, Inc.$523
- Novartis$430
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$240%
- Food & beverage$6,716100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $907 |
| UCB, Inc. | 37 | $826 |
| Teva Pharmaceuticals USA, Inc. | 61 | $572 |
| Biogen | 33 | $570 |
| Supernus Pharmaceuticals, Inc. | 31 | $523 |
| Novartis | 26 | $430 |
| Bristol Myers Squibb | 29 | $356 |
| SK Life Science, Inc. | 17 | $323 |
| Genentech USA, Inc. | 15 | $268 |
| Argenx US, Inc. | 7 | $185 |
| Amgen(2 entities) | 9 | $185 |
| Lundbeck LLC | 9 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $137 |
| EMD Serono, Inc. | 8 | $132 |
| Biohaven Pharmaceuticals, Inc. | 8 | $115 |
| AstraZeneca | 6 | $107 |
| Jazz Pharmaceuticals Inc. | 5 | $101 |
| Amneal Pharmaceuticals LLC | 6 | $92 |
| Sanofi | 4 | $76 |
| Neurocrine Biosciences, Inc. | 4 | $73 |
| Acorda Therapeutics, Inc | 3 | $66 |
| Kyowa Kirin, Inc. | 3 | $62 |
| Avanir Pharmaceuticals, Inc. | 4 | $60 |
| Pfizer | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Octapharma USA, Inc. | 1 | $46 |
| Neurelis, Inc. | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 1 | $31 |
| Grifols USA, LLC | 2 | $30 |
| Harmony Biosciences LLC | 2 | $30 |
| Livanova USA, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$6,748 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 57 | $381,092 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $325,746 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $137,143 |
| BetaseronInterferon Beta-1b | 14 | $136,539 |
| CopaxoneGlatiramer Acetate | 11 | $78,942 |
| AustedoDeutetrabenazine | 12 | $59,462 |
| QuliptaAtogepant | 18 | $25,132 |
| XcopriCenobamate | 12 | $19,821 |
| Glatiramer Acetate | 12 | $16,960 |
| TrileptalOxcarbazepine | 14 | $15,348 |
| Emgality PenGalcanezumab-Gnlm | 15 | $12,382 |
| Levetiracetam | 306 | $11,962 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,860 |
| Galantamine ErGalantamine Hbr | 84 | $7,779 |
| Oxcarbazepine | 107 | $7,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $30 | $381,09257 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo | $572 | $138,40423 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $137 | $137,14326 claims |
| AbbVieQulipta | $907 | $25,13218 claims |
| SK Life Science, Inc.Xcopri | $323 | $19,82112 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $92 | $2,37926 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $1,850138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.
Other neurology in Odessa
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.